On June 17th we held our Annual General Meeting in Zürich. We presented our strategic focus to fully concentrate on developing individualized therapeutic tumour vaccines for oncology patients. We have enhanced our organisation and external partner network to further pursue our goal to establish a Biotech company whose products will demonstrate clinical efficacy with favourable safety profile for oncologic patients and are pushing for international expansion by opening a new EU and US R&D Headquarter in Vienna, Austria and are taking immediate steps to enter the Asia Pacific Region.
